Pall sets up Singapore processing COE
The facility in Singapore’s Gemini Science Park II will provide process demonstration, validation support and training capabilities to pharmaceutical and biopharmaceutical manufacturers operating in the country.
Yves Baratelli, president of Pall’s life sciences division, said: “Pall’s new Singapore Life Sciences Centre of Excellence is representative of our global strategy of investing in high-growth areas where the demand for biotechnology process development and training is acute. It will serve as a central hub for our business and operational activities across the region.
This was echoed by president of Pall Asia Eric Garnier, who said: “The Singapore Life Sciences Centre of Excellence consolidates training and technical services, making it unparalleled as a resource for biotechnology companies seeking solutions for their process challenges.
“Biotechnology drugs and biologically derived vaccines are filtration and purification intensive. Pall is singularly well positioned to meet the growing market demand for this expertise.”
According to data from the Singapore Economic Development Board (EDB), seven of the top 10 global pharmaceutical companies have manufacturing facilities in Singapore.
And while this influx of manufacturers initially focused on the production of traditional small-molecule pharmaceuticals, in recent years there has been exceptional growth in biologics and vaccine manufacturing, with six new biologics and vaccines plants coming on-stream in the last 36 months.
The new 430 sqm facility will offer Pall’s full range of processing and filtration technologies as well as its process monitoring platforms.
The facility also offers a simulated cGMP training environment and contains a state-of-the-art seminar and training theatre.
